You are here

  • Home
  • Archive
  • Volume 77, Issue 5
  • Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study

Citation Tools

Article menu
Download PDFPDF
Clinical and epidemiological research
Extended report
Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Taylor PC, Schiff MH, Wang Q, et al
Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study
Annals of the Rheumatic Diseases 2018;77:658-666.